Standard Vape announces a COVID-19 animal study with Bioneeds India Private Limited, with testing set to begin on the SVAP Nano Nitric Oxide Dry Powder Inhaler as a potential COVID-19 treatment. The company identifies Neo-Virucide, Inc. as its wholly owned subsidiary in the announcement.
Standard Vape Corporation announces an animal study and financing related to its COVID-19 program. The company says animal testing facilities have been selected for its SVAP Nano Nitric Oxide Dry Powder Inhaler, which it describes as a potential COVID-19 treatment.
Standard Vape Corporation says it acquired Neo-Virucide, Inc. on April 14, 2020. The headline describes the new subsidiary as having a potential COVID-19 treatment.
Xuan Wu International Group Holding Company announces that its controlled subsidiary reaches an agreement to develop nicotine nanoparticles for the vaping industry.
